Annovis Bio Inc (ANVS)
NYSE:ANVS
Want to see ANVS full AI Analyst Report?
ANVS Stock Chart & Stats
$1.87
-$0.04(-0.79%)
At close: 4:00 PM EST
$1.87
-$0.04(-0.79%)
Day’s Range― - ―
52-Week Range$1.54 - $5.50
Previous CloseN/A
Volume368.97K
Average Volume (3M)1.16M
Market Cap
$64.44M
Enterprise Value$23.55M
Total Cash (Recent Filing)$14.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Aug 18, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding34,646,870
10 Day Avg. Volume1,528,156
30 Day Avg. Volume1,162,108
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$12.50Price Target Upside568.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Reported Debt / Balance-sheet FlexibilityThe company reports no debt across periods, which reduces fixed financing obligations and interest burdens. This structural advantage gives management flexibility to fund trials via equity or partnerships, lowering insolvency risk and preserving strategic optionality over the medium term.
Late-stage Lead Asset (Phase 3 Buntanetap)Advancing a lead asset into Phase 3 materially de-risks the pre-commercial profile compared with earlier-stage programs. Successful Phase 3 execution can unlock regulatory milestones, partner/licensing opportunities and an eventual commercial pathway, improving long-term revenue prospects and strategic optionality.
Demonstrated Access To Capital MarketsRepeated recent equity transactions show the company can tap public markets to secure funding for clinical programs. This persistent access supports continued Phase 3 execution and working capital needs, extending runway and enabling strategic choices without immediate reliance on debt markets.
Bears Say
Zero Revenue And Persistent Operating LossesThe company reports no product revenue and sustained operating losses, a structural feature of pre-commercial biotech that implies continued dependence on external funding. Over the medium term this raises execution risk and means valuation and business continuity hinge on clinical success rather than cash generation.
Worsening Cash Burn And Volatile Free Cash FlowMaterially worsening cash burn and highly volatile free cash flow reduce predictability of runway and capital needs. This structural instability forces frequent financing, constrains strategic flexibility, and increases execution risk for multi-year clinical programs absent sustained funding or partnerships.
Reliance On Dilutive Equity FinancingsThe company’s repeated use of equity and warrant offerings to fund trials signals structural reliance on dilutive capital. Over time this reduces existing shareholders' ownership and can pressure management to prioritize near-term trial milestones or partnerships, potentially limiting long-term upside if clinical outcomes falter.
Annovis Bio News
ANVS FAQ
What was Annovis Bio Inc’s price range in the past 12 months?
Annovis Bio Inc lowest stock price was $1.54 and its highest was $5.50 in the past 12 months.
What is Annovis Bio Inc’s market cap?
Annovis Bio Inc’s market cap is $64.44M.
When is Annovis Bio Inc’s upcoming earnings report date?
Annovis Bio Inc’s upcoming earnings report date is Aug 18, 2026 which is in 76 days.
How were Annovis Bio Inc’s earnings last quarter?
Annovis Bio Inc released its earnings results on May 15, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.395 by -$0.235.
Is Annovis Bio Inc overvalued?
According to Wall Street analysts Annovis Bio Inc’s price is currently Undervalued.
Does Annovis Bio Inc pay dividends?
Annovis Bio Inc does not currently pay dividends.
What is Annovis Bio Inc’s EPS estimate?
Annovis Bio Inc’s EPS estimate is -0.46.
How many shares outstanding does Annovis Bio Inc have?
Annovis Bio Inc has 34,646,870 shares outstanding.
What happened to Annovis Bio Inc’s price movement after its last earnings report?
Annovis Bio Inc reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.395. Following the earnings report the stock price went down -3.286%.
Which hedge fund is a major shareholder of Annovis Bio Inc?
Currently, no hedge funds are holding shares in ANVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (568.45% Upside)
$12.50 (568.45% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.55%
12-Months-Change
Fundamentals
Return on Equity
-318.08%
Trailing 12-Months
Asset Growth
-39.25%
Trailing 12-Months
Company Description
Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$12.50
▲(568.45% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Ownership Overview
13.92% Insiders
3.17% Mutual Funds
1.18% Other Institutional Investors
79.25% Public Companies and
Individual Investors